{
  "slides": [
    {
      "slide_number": 1,
      "title": "CRISPR: From Discovery to Clinic",
      "content": "A concise tour from bacterial immunity to first‑in‑class human therapies—science, delivery, safety, ethics, and markets.",
      "slide_design": "Full-bleed hero with bold headline and subtle helix motif",
      "imagery": "3D render: SpCas9 bound to a DNA duplex (PDB-inspired), shallow depth of field; cool lab blues/teals with soft rim lighting; faint bokeh of pipettes and microcentrifuge tubes in the far background"
    },
    {
      "slide_number": 2,
      "title": "Programmable Medicine",
      "content": "Guided by a short RNA, CRISPR tools cut, nick, or rewrite DNA/RNA—turning sequence into a therapeutic address.",
      "slide_design": "Minimalist, center‑justified typography on a dark micro‑grid texture",
      "imagery": "Foreground iconography: stylized guide RNA + scissors overlaying a DNA helix; high contrast on a midnight‑navy gradient with subtle glow"
    },
    {
      "slide_number": 3,
      "title": "Presentation Roadmap",
      "content": [
        "1. Discovery & Key Figures",
        "2. How CRISPR Works (mechanism diagram)",
        "3. Breakthroughs Timeline",
        "4. Delivery Modalities (AAV, LNP, ex vivo)",
        "5. Therapeutic Pipeline Landscape",
        "6. Market Outlook (size & segments)",
        "7. Clinical Risks, Ethics & Regulation",
        "8. Case Studies",
        "9. What’s Next: Future Outlook"
      ],
      "slide_design": "Agenda slide with numbered list, ample white space, and clear section dividers",
      "imagery": ""
    },
    {
      "slide_number": 4,
      "title": "Key Figures",
      "content": {
        "jennifer_doudna": {
          "name": "Jennifer Doudna, PhD",
          "background": [
            "UC Berkeley biochemist; co-discovered programmable CRISPR-Cas9 genome editing (2012)",
            "Pioneered governance and ethical discourse for genome editing",
            "2020 Nobel Prize in Chemistry (with Emmanuelle Charpentier)"
          ],
          "quote": "This technology gives us a way to rewrite the code of life. With that power comes profound responsibility."
        },
        "emmanuelle_charpentier": {
          "name": "Emmanuelle Charpentier, PhD",
          "background": [
            "Microbiologist who identified tracrRNA and co-invented the CRISPR-Cas9 editing system",
            "Founding and scientific leadership at the Max Planck Unit for the Science of Pathogens",
            "2020 Nobel Prize in Chemistry"
          ],
          "quote": "CRISPR is a simple concept with transformative implications when directed with precision and care."
        }
      },
      "slide_design": "Two-column layout with scientific portraits above bios and quotes",
      "imagery": "Crisp, high-key portraits of Doudna and Charpentier on neutral backgrounds; light teal accent bars under each name"
    },
    {
      "slide_number": 5,
      "title": "How CRISPR Works",
      "content": {
        "diagram_layers": [
          "Target selection: Cas9 scans DNA for a PAM (e.g., NGG) and the 20-nt guide RNA (gRNA) base-pairs with the protospacer.",
          "Cutting: Cas9’s HNH and RuvC domains cleave opposite strands to create a double-strand break (DSB).",
          "Repair path A—NHEJ: Error-prone repair introduces small indels, often yielding gene knockout.",
          "Repair path B—HDR: With a donor template, precise edits/insertions are made at the break site."
        ],
        "editor_variants": [
          "Base editors (ABE/CBE): nCas9 or dCas9 fused to a deaminase; single-base conversions (A↔G, C↔T) without DSB.",
          "Prime editor: nCas9 fused to reverse transcriptase with a pegRNA; installs small insertions/deletions/substitutions with minimal cutting."
        ],
        "glossary": {
          "gRNA": "Guide RNA that directs the nuclease to a matching DNA sequence",
          "PAM": "Protospacer Adjacent Motif required for nuclease binding (e.g., NGG for SpCas9)",
          "RNP": "Ribonucleoprotein complex of Cas protein and gRNA, used for transient editing"
        }
      },
      "slide_design": "Annotated mechanism diagram with two outcome branches (NHEJ vs HDR) and callout insets for base/prime editing",
      "imagery": "Four-panel vector diagram: 1) PAM + gRNA targeting (label 'PAM = NGG'); 2) Cas9 creates DSB; 3) NHEJ leading to indels (frameshift icon); 4) HDR using donor template; side insets depict base and prime editors with clear legends; clean sans-serif labels and directional arrows"
    },
    {
      "slide_number": 6,
      "title": "Breakthroughs Timeline",
      "content": {
        "timeline": [
          {
            "year": "2012",
            "milestone": "Programmable CRISPR-Cas9 editing",
            "proof_point": "In vitro demonstration of RNA-guided DNA cleavage (Jinek et al., Science)"
          },
          {
            "year": "2013",
            "milestone": "Editing in mammalian cells",
            "proof_point": "CRISPR-Cas9 enables targeted gene disruption and HDR in human cells"
          },
          {
            "year": "2016",
            "milestone": "Base editing introduced",
            "proof_point": "Cytosine and adenine base editors expand precise, DSB-free editing"
          },
          {
            "year": "2019",
            "milestone": "Prime editing unveiled",
            "proof_point": "Versatile small insertions/deletions/substitutions without donor DNA"
          },
          {
            "year": "2020",
            "milestone": "Nobel Prize in Chemistry",
            "proof_point": "Recognition of Doudna and Charpentier for CRISPR-Cas9"
          },
          {
            "year": "2021",
            "milestone": "First in vivo CRISPR infusion shows strong target knockdown",
            "proof_point": "ATTR program demonstrates dose-dependent TTR reduction after a single IV dose"
          },
          {
            "year": "2022",
            "milestone": "First in-human base editing data",
            "proof_point": "In vivo base editing of PCSK9 shows sustained LDL-C lowering"
          },
          {
            "year": "2023–24",
            "milestone": "First regulatory approvals of a CRISPR therapy",
            "proof_point": "Exagamglogene autotemcel (exa-cel/CASGEVY) approved for severe SCD; broader indications and regions follow"
          }
        ]
      },
      "slide_design": "Horizontal timeline with milestone markers, succinct captions, and small modality icons",
      "imagery": "Clean, left-to-right timeline; iconography: pipette (2012), human cell (2013), A/G and C/T glyphs (2016), pencil icon (prime editing), Nobel medallion (2020), IV bag + liver (2021), heart/lipid icon (2022), regulatory checkmark stamp (2023–24)"
    },
    {
      "slide_number": 7,
      "title": "Delivery Modalities: Getting Editors to Cells",
      "content": {
        "modalities": {
          "AAV": {
            "works_best_for": "In vivo editing in tissues with suitable serotypes (e.g., eye, muscle, CNS subtypes)",
            "pros": [
              "Strong tropism and transduction",
              "Single-dose potential",
              "Long-term expression (for some applications)"
            ],
            "constraints": [
              "Capsid size limits (~4.7 kb) constrain editor payloads",
              "Pre-existing immunity/re-dosing challenges",
              "Potential for vector integration and liver toxicity at high doses"
            ],
            "notables": [
              "EDIT-101 (AAV5) for LCA10",
              "Dual-AAV or compact nucleases (SaCas9) mitigate payload limits"
            ]
          },
          "LNP": {
            "works_best_for": "In vivo delivery to liver; expanding to extrahepatic targets via ligand/capsid engineering",
            "pros": [
              "Transient expression reduces prolonged exposure risk",
              "Manufacturable at scale; modular chemistry",
              "Amenable to repeat dosing in some contexts"
            ],
            "constraints": [
              "Hepatocyte bias limits tropism",
              "Infusion-related reactions; dose ceiling considerations",
              "Endosomal escape efficiency is a key bottleneck"
            ],
            "notables": [
              "NTLA-2001 (Cas9 mRNA + gRNA LNP) for ATTR",
              "VERVE-101 (ABE mRNA + gRNA LNP) for PCSK9"
            ]
          },
          "Electroporation (ex vivo)": {
            "works_best_for": "Autologous/allogeneic cell therapies (HSPCs, T cells, NK cells)",
            "pros": [
              "Transient RNP delivery—minimal off-target window",
              "High editing rates and multiplex capability",
              "No viral DNA integration"
            ],
            "constraints": [
              "Manufacturing complexity and cost",
              "Conditioning regimens for reinfusion (e.g., myeloablation)",
              "Logistics of cell collection and release testing"
            ],
            "notables": [
              "Exa-cel/CASGEVY (BCL11A enhancer edit) for SCD/TDT",
              "Multiplex-edited allogeneic CAR-T programs"
            ]
          },
          "Non-viral/Other": {
            "works_best_for": "Emerging systemic/extracellular targets; specialized tissues",
            "pros": [
              "Potential for targeted delivery with ligands/antibodies",
              "Avoids viral immunity concerns"
            ],
            "constraints": [
              "Lower transfection efficiency historically",
              "Formulation stability and biodistribution challenges"
            ],
            "notables": [
              "Virus-like particles (VLPs)",
              "Polymeric/ionizable lipid hybrids",
              "Physical methods (hydrodynamic, microinjection for ocular)"
            ]
          }
        }
      },
      "slide_design": "Comparative tiles with modality icons, pros/cons bullets, and exemplar programs",
      "imagery": "Four-tile layout: 1) AAV capsid wireframe; 2) LNP micelles with branching PEG; 3) Electroporation cuvette with stylized pulse; 4) Antibody-targeted nanoparticle schema; clean vector style on off-white"
    },
    {
      "slide_number": 8,
      "title": "Therapeutic Pipeline Landscape",
      "content": {
        "categories": [
          {
            "area": "Hematology (ex vivo)",
            "indications": [
              "Sickle cell disease",
              "β‑thalassemia"
            ],
            "representative_programs": [
              "Exa-cel/CASGEVY (BCL11A enhancer KO)",
              "Base-edited HSPCs (e.g., BEAM-101)"
            ]
          },
          {
            "area": "Cardio‑metabolic (in vivo, liver)",
            "indications": [
              "ATTR amyloidosis",
              "Hypercholesterolemia (PCSK9)",
              "Lp(a) lowering"
            ],
            "representative_programs": [
              "NTLA‑2001 (TTR KO)",
              "VERVE‑101 (PCSK9 ABE)"
            ]
          },
          {
            "area": "Ophthalmology (in vivo, ocular)",
            "indications": [
              "LCA10",
              "Choroideremia"
            ],
            "representative_programs": [
              "EDIT‑101 (CEP290 intronic splice edit)"
            ]
          },
          {
            "area": "Oncology (ex vivo)",
            "indications": [
              "B‑cell malignancies",
              "Solid tumors (investigational)"
            ],
            "representative_programs": [
              "Multiplex-edited allogeneic CAR‑T/NK (PD‑1, TRAC, B2M edits)"
            ]
          },
          {
            "area": "Rare genetic (various)",
            "indications": [
              "AATD",
              "DMD",
              "CNS and hearing loss targets (preclinical)"
            ],
            "representative_programs": [
              "Emerging in vivo prime/base editors; targeted LNPs/capsids"
            ]
          }
        ],
        "stage_counts (approximate)": [
          {
            "stage": "Discovery/Preclinical",
            "programs": "200+"
          },
          {
            "stage": "Phase 1",
            "programs": "~40"
          },
          {
            "stage": "Phase 2",
            "programs": "~10"
          },
          {
            "stage": "Phase 3",
            "programs": "3–5"
          },
          {
            "stage": "Approved",
            "programs": "1 (2023–24)"
          }
        ],
        "approved_therapy": {
          "name": "Exagamglogene autotemcel (exa‑cel/CASGEVY)",
          "modality": "Ex vivo CRISPR/Cas9 RNP edit of autologous HSPCs (BCL11A enhancer)",
          "indications": [
            "Severe sickle cell disease",
            "Transfusion‑dependent β‑thalassemia"
          ],
          "status_snapshot": "First CRISPR therapy approved in multiple regions (2023–24)"
        }
      },
      "slide_design": "Pipeline heatmap/matrix: rows by disease area, columns by stage; callout badge for the first approval",
      "imagery": ""
    },
    {
      "slide_number": 9,
      "title": "Market Outlook: CRISPR Therapeutics",
      "content": {
        "chart_title": "Projected Global CRISPR Therapeutics Revenue (illustrative scenario)",
        "units": "USD billions",
        "chart_data": [
          {
            "year": "2024",
            "total": 0.6,
            "segments": {
              "ex_vivo_cell_therapies": 0.5,
              "in_vivo_liver": 0.05,
              "in_vivo_extrahepatic": 0.03,
              "ocular": 0.02
            }
          },
          {
            "year": "2027",
            "total": 6,
            "segments": {
              "ex_vivo_cell_therapies": 3,
              "in_vivo_liver": 2.2,
              "in_vivo_extrahepatic": 0.6,
              "ocular": 0.2
            }
          },
          {
            "year": "2030",
            "total": 18,
            "segments": {
              "ex_vivo_cell_therapies": 7,
              "in_vivo_liver": 7,
              "in_vivo_extrahepatic": 3,
              "ocular": 1
            }
          }
        ],
        "assumptions": [
          "Progressive approvals in hematology and liver indications",
          "Manufacturing scale-up reduces COGS and expands access",
          "Extrahepatic delivery breakthroughs by late decade",
          "Pricing pressure partially offset by outcomes-based contracts"
        ],
        "notes": "For planning discussion only; directional and non-binding; not investment advice"
      },
      "slide_design": "Stacked bar chart with bold accent color for ex vivo (blue) and complementary hues for in vivo segments; clear labels and gridlines",
      "imagery": "Crisp stacked bar chart graphic; left y-axis labeled in billions; legend keyed to four segments; subtle shadow and high-contrast annotations for CAGR arrows"
    },
    {
      "slide_number": 10,
      "title": "Clinical Risks, Ethics & Regulation",
      "content": {
        "safety_risks_and_mitigations": [
          {
            "risk": "Off-target edits",
            "mitigations": [
              "High-fidelity nucleases (e.g., eSpCas9, HiFi Cas9, Cas12a)",
              "Guide optimization (truncated/chemically modified gRNAs)",
              "Orthogonal off-target mapping (GUIDE-seq, CIRCLE-seq, CHANGE-seq, DISCOVER-Seq)",
              "Dose minimization and transient delivery (RNP, mRNA/LNP)"
            ]
          },
          {
            "risk": "On-target complexity (large deletions, rearrangements, p53 activation)",
            "mitigations": [
              "Favor base/prime editors when feasible",
              "Allele-aware design; limit cut frequency",
              "Long-read sequencing and junction PCR in release testing",
              "Functional assays for tumor suppressor pathways"
            ]
          },
          {
            "risk": "Vector-related genotoxicity/toxicity (AAV integration, high-dose hepatotoxicity)",
            "mitigations": [
              "Lower doses with potent promoters/capsids",
              "Integration site analysis; biodistribution/tox study rigor",
              "Patient selection and LFT monitoring, steroid protocols"
            ]
          },
          {
            "risk": "Immunity to Cas proteins or vectors",
            "mitigations": [
              "Pre-screen for neutralizing antibodies where relevant",
              "Use humanized/less-immunogenic enzymes; transient exposure",
              "Prophylaxis and monitoring for infusion reactions"
            ]
          },
          {
            "risk": "Manufacturing and product variability",
            "mitigations": [
              "In-process controls, potency assays, deep sequencing QC",
              "Closed, automated systems; standardized analytics"
            ]
          }
        ],
        "monitoring_toolkit": [
          "Amplicon NGS and WGS (short + long read)",
          "GUIDE-seq/CIRCLE-seq/CHANGE-seq for off-target discovery",
          "Vector integration assays",
          "Clinical labs: hematology, chemistry, immunogenicity panels",
          "Long-term follow-up registries (up to 15 years for gene-modifying therapies)"
        ],
        "ethics_topics": [
          "Somatic vs. germline boundary—therapeutic use only in humans",
          "Informed consent and long-term data stewardship",
          "Equitable access and affordability",
          "Pediatric/rare disease risk–benefit calculus",
          "Avoiding enhancement uses and guarding against misuse"
        ],
        "regulatory_overview": {
          "US_FDA": "CBER draft guidance (2022): Human Gene Therapy Products Incorporating Human Genome Editing; expectations for off-target assessment, CMC, and long-term follow-up",
          "EU_EMA": "ATMP framework; gene editing under gene therapy guidelines; CHMP methodological guidance for biodistribution, shedding, and long-term safety",
          "UK_MHRA": "ILAP/Innovation pathways facilitate accelerated access with robust risk management",
          "WHO": "2021 recommendations for governance and oversight of human genome editing"
        }
      },
      "slide_design": "Two-column layout: left pane ‘Risks & Mitigations’ checklist; right pane ‘Ethics & Regulatory Guardrails’",
      "imagery": ""
    },
    {
      "slide_number": 11,
      "title": "Case Studies & What’s Next",
      "content": {
        "case_studies": [
          {
            "program": "Exagamglogene autotemcel (exa‑cel/CASGEVY)",
            "modality": "Ex vivo CRISPR/Cas9 RNP; autologous HSPC edit (BCL11A enhancer)",
            "indication": "Severe sickle cell disease; transfusion‑dependent β‑thalassemia",
            "key_results": [
              "High rates of elimination of severe vaso‑occlusive crises (SCD)",
              "Durable HbF induction; transfusion independence in many TDT patients"
            ],
            "notes": "Requires myeloablation and specialized manufacturing/logistics"
          },
          {
            "program": "NTLA‑2001",
            "modality": "In vivo CRISPR/Cas9 via LNP (mRNA + gRNA)",
            "indication": "Hereditary transthyretin amyloidosis (ATTR)",
            "key_results": [
              "Single IV dose achieves dose‑dependent TTR reductions (often >80–90%)"
            ],
            "notes": "Demonstrates systemic in vivo editing feasibility in humans"
          },
          {
            "program": "VERVE‑101",
            "modality": "In vivo adenine base editor (ABE) via LNP",
            "indication": "Heterozygous familial hypercholesterolemia (PCSK9)",
            "key_results": [
              "Sustained LDL‑C lowering in early clinical data"
            ],
            "notes": "First clinical base editing program; long‑term durability under observation"
          }
        ],
        "whats_next": [
          "Prime editing enters/approaches clinical testing for precise corrections",
          "Targeted LNPs and next‑gen capsids broaden beyond liver (lung, muscle, CNS)",
          "In vivo gene insertion and safe‑harbor strategies for durable replacement",
          "Multiplex editing for off‑the‑shelf cell therapies with logic gating",
          "CRISPRi/a and epigenome editing for reversible gene control",
          "Manufacturing scale‑out, closed systems, and outcomes‑based pricing to expand access"
        ]
      },
      "slide_design": "Three case tiles with micro‑graphics and a right‑hand ‘What’s Next’ column",
      "imagery": "Triptych: 1) Stylized bone marrow culture dish with glowing HSPCs; 2) LNPs approaching hepatocytes with endosomal escape arrows; 3) Arterial cross‑section with diminishing LDL particles; clean vector, high contrast"
    }
  ]
}